Aclaris Therapeutics, Inc. (ACRS) Form 424B5 — Oct 27, 2026
Aclaris Therapeutics priced an underwritten offering of 7,785,714 shares of common stock plus pre-funded warrants to purchase 6,500,000 additional shares at $3.50 per share, for gross proceeds of approximately $50.0 million. The price represents a 7.7% discount to the prior close of $3.79, with net proceeds of roughly $46.7 million earmarked for R&D on its pipeline and general corporate purposes. The offering dilutes existing holders by roughly 10%, growing shares outstanding from 139.8 million to about 147.6 million (plus warrant shares), with immediate dilution of $2.06 per share to new investors against pro forma net tangible book value of $1.44 per share.
Key figures
- Gross Proceeds
- 49999934
- Offering Price
- 3.5
- Shares Offered
- 7785714
- Net Proceeds
- 46700000
- Lockup Period
- 60 days
- Dilution Per New Share
- 2.06
- Discount To Prior Close
- $3.50 vs $3.79 last sale on Oct 26, 2026
- Underwriting Discount
- 3000000
- Prefunded Warrant Price
- 3.49999
- New Shares Vs Outstanding
- ~10.2% (14,285,714 of 139,824,273)
- Prefunded Warrant Shares
- 6500000
- Shares Outstanding Pre Offering
- 139824273
- Prefunded Warrant Exercise Price
- 0.00001
- Shares Outstanding Post Offering
- 147609987
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.